IL18 and amyloidosis: Emerging research focuses on epigenetic regulation of MEFV, potential biomarkers of disease activity (such as SAA or interleukin-18 levels), and “treat-to-target” strategies that aim to suppress subclinical inflammation and prevent amyloidosis [2,6].